KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Interest & Investment Income (2016 - 2025)

Arbutus Biopharma's Interest & Investment Income history spans 13 years, with the latest figure at $952000.0 for Q3 2025.

  • For Q3 2025, Interest & Investment Income fell 45.51% year-over-year to $952000.0; the TTM value through Sep 2025 reached $4.7 million, down 29.32%, while the annual FY2024 figure was $6.6 million, 15.77% up from the prior year.
  • Interest & Investment Income for Q3 2025 was $952000.0 at Arbutus Biopharma, down from $1.0 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $1.8 million in Q2 2024 and bottomed at $27000.0 in Q3 2021.
  • The 5-year median for Interest & Investment Income is $1.0 million (2025), against an average of $935947.4.
  • The largest annual shift saw Interest & Investment Income crashed 88.7% in 2021 before it soared 3043.33% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $30000.0 in 2021, then surged by 3043.33% to $943000.0 in 2022, then surged by 55.36% to $1.5 million in 2023, then fell by 0.07% to $1.5 million in 2024, then crashed by 34.97% to $952000.0 in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Interest & Investment Income are $952000.0 (Q3 2025), $1.0 million (Q2 2025), and $1.2 million (Q1 2025).